trending Market Intelligence /marketintelligence/en/news-insights/trending/VmjpKh7RFv5WXPG-c8DvBg2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Pfizer's arthritis drug gets favorable vote from FDA panel

Blog

Banking Essentials Newsletter - February Edition

Blog

Message in a (Word)Cloud

Six trends shaping the industries and sectors we cover in 2021

Six trends shaping the industries and sectors we cover in 2021


Pfizer's arthritis drug gets favorable vote from FDA panel

Pfizer Inc. said the U.S. Food and Drug Administration's Arthritis Advisory Committee voted 10 to 1 to recommend approval of Xeljanz to treat adults with active psoriatic arthritis.

The company's supplemental new drug application for the indication is under review by the FDA, with a decision expected by December.

Xeljanz is currently approved to treat adults with moderately to severely active rheumatoid arthritis.